Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HOWARD J RUBENSTEIN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1376598086
CMS profile
244149
Location
SARALAND, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,250.93

61 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,250.93 61

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 61 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HOWARD J RUBENSTEIN

NPI 1376598086 · CMS profile ID 244149

Allopathic & Osteopathic Physicians / Family Medicine

SARALAND, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 61 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1376598086?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HOWARD J RUBENSTEIN, NPI 1376598086, CMS profile ID 244149. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 61 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376598086?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). HOWARD J RUBENSTEIN, NPI 1376598086, CMS profile ID 244149. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 61 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376598086?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
HOWARD J RUBENSTEIN, NPI 1376598086, CMS profile ID 244149, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 61 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1376598086?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

61 matching records · $1,250.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 61 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 61.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $17.4912/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819177249 CMS
Lilly USA, LLC $13.3411/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819177261 CMS
PFIZER INC. $18.5411/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833174777 CMS
PFIZER INC. $11.5411/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833444879 CMS
AbbVie Inc. $29.0710/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795897381 CMS
Amarin Pharma Inc. $16.3910/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815043161 CMS
Lilly USA, LLC $12.8110/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819189819 CMS
DEXCOM, INC. $13.3310/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845296217 CMS
Novo Nordisk Inc $1.2810/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811269921 CMS
Novo Nordisk Inc $13.7910/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811675161 CMS
Merck Sharp & Dohme Corporation $16.2810/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848647473 CMS
Novartis Pharmaceuticals Corporation $16.4109/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813215411 CMS
Lilly USA, LLC $15.2509/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819189815 CMS
AbbVie Inc. $14.2509/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795897377 CMS
Amarin Pharma Inc. $18.5809/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815160577 CMS
PFIZER INC. $16.9209/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833396905 CMS
Amgen Inc. $14.5309/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825357611 CMS
DEXCOM, INC. $12.0608/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845296215 CMS
Lilly USA, LLC $18.2908/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819087061 CMS
PFIZER INC. $18.5908/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832832231 CMS
Novo Nordisk Inc $16.5908/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811561753 CMS
AstraZeneca Pharmaceuticals LP $125.0008/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830096241 CMS
Merck Sharp & Dohme Corporation $17.9708/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848516349 CMS
Xeris Pharmaceuticals, Inc. $20.6907/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837443091 CMS
Biohaven Pharmaceuticals, Inc. $22.0807/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852606927 CMS
Lilly USA, LLC $11.6407/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818565285 CMS
Amarin Pharma Inc. $18.5807/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815160573 CMS
PFIZER INC. $15.0607/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833473587 CMS
DEXCOM, INC. $17.6506/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845296213 CMS
Esperion Therapeutics, Inc. $125.0006/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838390815 CMS
Daiichi Sankyo Inc. $20.8906/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836298767 CMS
AbbVie Inc. $12.9506/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795897373 CMS
Merck Sharp & Dohme Corporation $19.7706/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848724209 CMS
Novo Nordisk Inc $16.4206/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811415167 CMS
Novo Nordisk Inc $64.8005/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811415161 CMS
Novo Nordisk Inc $19.2205/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811561747 CMS
PFIZER INC. $11.6805/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833560419 CMS
Amryt Pharma Holdings Ltd $24.4405/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832287313 CMS
DEXCOM, INC. $14.1705/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845296211 CMS
Amarin Pharma Inc. $19.4404/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815160579 CMS
Novo Nordisk Inc $19.6404/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810627715 CMS
PFIZER INC. $11.7204/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832740919 CMS
Lilly USA, LLC $16.5104/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819177245 CMS
PFIZER INC. $13.9604/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833420855 CMS
Lilly USA, LLC $16.7904/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819190317 CMS
Merck Sharp & Dohme Corporation $15.3704/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848399135 CMS
GlaxoSmithKline, LLC. $12.2004/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803144635 CMS
PFIZER INC. $17.9903/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833575049 CMS
Merck Sharp & Dohme Corporation $13.4503/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848488077 CMS
Lilly USA, LLC $13.8403/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819177257 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,704.05 108
PY2020 $792.39 63
PY2021 $1,250.93 61
PY2022 $1,424.94 82
PY2023 $2,008.26 62
PY2025 $1,028.79 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $290,410.38 20
PY2024 Principal investigator $582,175.45 67
PY2023 Principal investigator $178,596.47 28
PY2022 Principal investigator $323,131.01 30
PY2021 Principal investigator $410,276.56 30
PY2020 Recipient $1,694.65 7
PY2020 Principal investigator $897,181.33 26
PY2019 Principal investigator $623,481.03 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,080.00 12/31/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 889829011
Principal investigator 1 ABBVIE INC. $506.00 12/31/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS - SA
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 889829013
Principal investigator 1 ABBVIE INC. $152.00 12/31/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS SAR
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 965540099
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,047.67 12/31/2022 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 914600305
Principal investigator 1 AstraZeneca Pharmaceuticals LP $354.12 12/31/2022 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 914604027
Principal investigator 1 ABBVIE INC. $2,425.00 12/07/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 889823287
Principal investigator 1 Bausch Health US, LLC $22,241.61 10/28/2022 Non-covered Recipient Entity
HOUSTON CENTER FOR CLINICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel-group Study of the Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C) No dispute reported 06/30/2026 960342509
Principal investigator 1 ABBVIE INC. $13,450.00 10/27/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 889817535
Principal investigator 1 ABBVIE INC. $12,894.00 10/11/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C No dispute reported 06/30/2026 889814021
Principal investigator 1 ABBVIE INC. $7,000.00 10/06/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 889813237
Principal investigator 1 ABBVIE INC. $8,950.00 10/06/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 889813273
Principal investigator 1 ABBVIE INC. $1,021.00 09/08/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C No dispute reported 06/30/2026 889809509
Principal investigator 1 CHIESI USA, INC. $1,000.00 09/01/2022 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A 52-WEEK, PLACEBO- AND ACTIVE- CONTROLLED (ROFLUMILAST, DALIRESP 500) STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DOSES OF CHF6001 DPI (TANIMILAST) AS ADD-ON TO MAINTENANCE TRIPLE THERAPY IN SUBJECTS WITH COPD AND CHRONIC BRONCHITIS. (PILLAR) (PI No dispute reported 06/30/2026 957725155
Principal investigator 1 ABBVIE INC. $1,021.00 08/04/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C No dispute reported 06/30/2026 889803249
Principal investigator 1 ABBVIE INC. $4,181.00 07/01/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C No dispute reported 06/30/2026 889798139
Principal investigator 1 ABBVIE INC. $1,021.00 06/23/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C No dispute reported 06/30/2026 889796829
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,605.92 06/16/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS
AN OPEN-LABEL EXTENSION TRIAL OF THE PHASE III LIPID-LOWERING TRIALS TO ASSESS THE EFFECT OF LONG TERM DOSING OF INCLISIRAN GIVEN AS SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH HIGH CARDIOVASCULAR RISK AND ELEVATED LDL-C No dispute reported 06/30/2026 909419909
Principal investigator 1 ABBVIE INC. $1,258.00 05/04/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 889789357
Principal investigator 1 ABBVIE INC. $5,888.00 05/04/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C No dispute reported 06/30/2026 889789359
Principal investigator 1 AstraZeneca Pharmaceuticals LP $11,950.00 03/16/2022 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 914595527
Principal investigator 1 Allergan, Inc. $6,706.95 03/08/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALSINC
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 864373195
Principal investigator 1 Allergan, Inc. $2,880.05 03/08/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALSINC
Clinical Trial (LIN-MD-66: PED Longterm safety study) No dispute reported 06/30/2026 864373513
Principal investigator 1 Allergan, Inc. $1,713.80 03/01/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALSINC
Clinical Trial (LIN-MD-66: PED Longterm safety study) No dispute reported 06/30/2026 864371717
Principal investigator 1 Allergan, Inc. $7,978.10 02/28/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALSINC
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 864371195
Principal investigator 1 Allergan, Inc. $1,510.50 02/17/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALSINC
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 864369877
Principal investigator 1 Allergan, Inc. $969.95 02/17/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALSINC
Clinical Trial (LIN-MD-66: PED Longterm safety study) No dispute reported 06/30/2026 864370007
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,118.89 01/26/2022 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 914592633
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $142,726.50 01/26/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALS INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF FIXED-DOSE BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN THE TREATMENT OF ADULTS WITH POST-TRAUMATIC STRESS DISORDER No dispute reported 06/30/2026 933760625
Principal investigator 1 Allergan, Inc. $21,295.20 01/12/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALSINC
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 864366599
Principal investigator 1 Allergan, Inc. $4,184.75 01/12/2022 Non-covered Recipient Entity
THE CENTER FOR CLINICAL TRIALSINC
Clinical Trial (LIN-MD-66: PED Longterm safety study) No dispute reported 06/30/2026 864366875